Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  XenoPort, Inc.    

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

XenoPort, Inc. : XenoPort Announces New Employment Inducement Award

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2012 | 11:05pm CET

XenoPort, Inc. (Nasdaq:XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Sayuri Ino, was granted restricted stock units representing an aggregate of 500 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the June 1, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort's board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is XenoPort's first U.S. Food and Drug Administration-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity and Parkinson's disease.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

Horizant is a registered U.S. trademark of GSK.

XENOPORT is a registered trademark of XenoPort, Inc.

Regnite is a registered trademark of Astellas.


XenoPort, Inc.
Jackie Cossmon, 408-616-7220
[email protected]

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on XENOPORT, INC.
2016 XENOPORT : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of..
2016 XENOPORT : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR..
2016 XENOPORT, INC. : SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigatio..
2016 XENOPORT SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation o..
2016 Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of ..
2016 Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, I..
2016 Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Inte..
2016 RYAN & MANISKAS, LLP : Announces Investigation of XenoPort, Inc.
2016 Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Xe..
2016 HARWOOD FEFFER LLP : Announces Investigation of XenoPort, Inc.
More news
News from SeekingAlpha
2016 New Oral Psoriasis Drug Tops Cellceutix Catalysts
2016 Biotechnology - The Perfect Yo-Yo
2016 Is This The Next REIT To Return 50%?
2016 Jay Z Sells Out To Apple
2016 GE's Next Big Energy Move
Income Statement Evolution
William G. Harris Chief Financial Officer & Senior VP-Finance
Richard K. Kim Chief Medical Officer & SVP-Clinical Development
William J. Rieflin Director
Jeryl L. Hilleman Director
Leslie B. Zacks Co-Secretary & Treasurer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659